The global Inflammatory Bowel Disease Treatment Market is benefiting from rising disease prevalence, growing adoption of advanced biologics, expanding access to targeted therapies, increasing awa...
Posted by Surbhi on July 09 2026 at 06:02 PM
public
IL-23 inhibitors in IBD treatment — the selective biologics targeting the p19 subunit of interleukin-23 (risankizumab/Skyrizi, guselkumab/Tremfya, mirikizumab/Omvoh) demonstrating superior effica...
